The company has not filed an annual or quarterly report since its FY2022 20-F, filed Mar 20, 2023. Its latest SEC filing is a SC 13G/A from Feb 12, 2024.
20-F for FY2022, filed Mar 20, 2023
The sections below describe the company as of the FY2022 annual report.
Sold antibodies and related research tools to academic and research institutions and life science companies.
20-F for FY2022, filed Mar 20, 2023We are a global life science company focused on identifying, developing, and distributing high quality reagents and tools for our customers…View ↗
Research use only (“RUO”) proteomic tools. These products include protein binding reagents, such as primary and secondary antibodies and…View ↗
CustomersView ↗
Academic and research institutions, and pharmaceutical, biotechnology and diagnostic companies, ordered directly through online and field sales channels or through distributors.
Yes. It kept 1 cent of every revenue dollar as net income in .
20-F for FY2022, filed Mar 20, 2023
Loading...
